A scientist works in a laboratory at the Novavax facility in Gaithersburg, Maryland, US. (Photographer: Jon Cherry/Bloomberg via Getty Images)

No­vavax fo­cus­es on vari­ant-spe­cif­ic vac­cines in ex­pand­ed deal with South Ko­re­an man­u­fac­tur­er

The roller­coast­er ride for No­vavax’s Covid-19 vac­cine has fi­nal­ly re­sult­ed in an emer­gency use au­tho­riza­tion from the FDA. How­ev­er, as the Omi­cron vari­ant spreads, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.